Study register · detail
Clear benefit
GRADE
Low
35 citations
Samplen = 150 Pat.
Duration1 year
ControlIndividuals with PTSD without cannabis use
EndpointPTSD symptom burden
Blindingn.a.
DesignProspektive Kohortenstudie (Real-World)
Cannabinoidvollspektrum
Key finding
Cannabis use was associated with significantly greater PTSD symptom reduction and a higher remission rate.
Summary
n=150 PTSD patients (73% male), prospective observation over 1 year: cannabis users (dispensary) vs. cannabis non-users. Cannabis group showed a greater reduction in PTSD symptom severity (group×time interaction=-0,32; 95% CI=-0,59 to -0,05; p=0,02). Cannabis users 2,57× more likely to be without a DSM-5 PTSD diagnosis at study end (95% CI=1,12–6,07; p=0,03).
P
PopulationAdults with PTSD diagnosis (DSM-5), n=150, mean age 50,67 years, 73% male; subgroups: cannabis users vs. non-users
I
InterventionPharmacy/dispensary cannabis (self-selected, naturalistic use over 12 months)
C
ControlIndividuals with PTSD without cannabis use (control group)
O
OutcomeSignificantly greater decrease in PTSD symptom burden in cannabis users vs. controls (group×time interaction=-0,32; 95% CI=-0,59 to -0,05; p=0,02); cannabis users 2,57× more likely to be without a DSM-5 PTSD diagnosis at study end (95% CI=1,12–6,07; p=0,03)
Confidence in the evidence
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
<b>Introduction:</b> Given the increasing availability and use of cannabis among individuals with post-traumatic stress disorder (PTSD) and the addition of PTSD as an eligible diagnosis in several U.S. medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined. <b>Materials and Methods:</b> This prospective study assessed PTSD symptoms and functioning every 3 months over the course of a year in two samples of participants diagnosed with PTSD: (1) those with PTSD using dispensary-obtained cannabis (cannabis users) and (2) those with PTSD, who do not use cannabis (controls). Linear mixed-effects models and generalized estimating equations tested whether trajectories of symptoms differed between the two subsamples. <b>Results:</b> A total of 150 participants (mean [standard deviation] age, 50.67 [15.26] years; 73% male) were enrolled in the study. Over the course of 1 year, the cannabis users reported a greater decrease in PTSD symptom severity over time compared to controls [group×time interaction=-0.32 (95% confidence interval [CI]=-0.59 to -0.05, <i>R</i><sup>2</sup>=0.13; <i>t</i>=-2.35, <i>p</i>=0.02). Participants who used cannabis were 2.57 times more likely to no longer meet DSM-5 criteria for PTSD at the end of the study observation period compared to participants who did not use cannabis (95% CI=1.12-6.07; <i>p</i>=0.03). <b>Conclusions:</b> This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. Randomized placebo-controlled trials are needed to assess safety and determine how different preparations of cannabis impact PTSD and functioning.
The impediment to action advances action.